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حتدمية جسيمة بعد بضع القزحية بالليزر يف مريض يتناول عالج ثنائي من 
مضادات تكتل الصفيحات الدموية )األسربين باألضافة اىل التيكاجريلور(
تقرير حالة ومراجعة لألدبيات
فريجيليو غالفي�ض، األيخاندرو تيللو، ني�ستور كارينو، والرت �سان�سيز، غابرييل فريدريك، نيكول�ض بالنكو
abstract: Massive hyphaema presentation after a laser iridotomy is very rare. We report a 63-year-old man with 
ischaemic heart disease on dual antiplatelet therapy (aspirin plus ticagrelor) who was diagnosed as a primary angle-closure 
suspect and was to undergo a neodymium-doped yttrium aluminium garnet laser iridotomy at Centro Oftalmológico 
Virgilio Galvis, Floridablanca, Colombia in 2016. While performing the iridotomy in the left eye, active bleeding occurred 
that finally filled approximately 75% of the anterior chamber. Intraocular pressure (IOP) increased to 62 mmHg. Mannitol 
and a topical dorzolamide/timolol were used to control the increase in IOP. The hyphaema slowly resolved over the 
following week without sequelae. This case revealed that massive hyphaema can complicate laser iridotomy in patients on 
dual antiplatelet therapy, although this is rare. Therefore, if patients are taking aspirin and ticagrelor, it would be advisable 
to stop the second medication if possible. In addition, sequential application of photocoagulation and photodisruption 
lasers might diminish the risk of significant bleeding.
Keywords: Iridectomy; Nd-YAG Laser; Hyphema; Platelet Aggregation Inhibitors; Angle-Closure Glaucoma; Ocular 
Hypertension; Case Report; Columbia.
امللخ�ص: ح�سول حتدمية ج�سيمة بعد ب�سع القزحية بالليزر هو امر نادر جًدا. نعر�ض هنا حالة رجل يبلغ من العمر 63 عاًما م�ساب مبر�ض نق�ض 
تروية القلب ويتلقى عالج ثنائي من م�سادات تكتل ال�سفيحات الدموية )الأ�سربين بالإ�سافة اإىل التيكاجريلور( والذي مت ت�سخي�سه كم�ستبه م�ساب 
بزرق اإن�سداد الزاوية الأويل وخ�سع لعملية ب�سع القزحية بالليزر العقيقي الذي ي�ستخدم اإيرتيوم الألومنيوم املن�سط بالنيودمييوم وذلك يف مركز 
فريجيليو غالفي�ض لطب العيون، فلوريدابالنكا ، كولومبيا يف عام 2016. اأثناء اإجراء عملية ب�سع القزحية يف العني الي�رسى، حدث نزيف ن�سط مالأ 
حوايل %75 من الغرفة الأمامية للعني. وزاد ال�سغط داخل العني اإىل 62 مم زئبق. مت ا�ستخدام مانيتول ودورزولميد/تيمولول مو�سعيا لل�سيطرة على 
زيادة ال�سغط داخل العني. وزال نزيف العني يف الأ�سبوع التايل دون م�ساعفات. ك�سفت هذه احلالة اأن التحدمية اجل�سيمة ميكن اأن حتدث كم�ساعفة 
لعملية ب�سع القزحية بالليزر يف املر�سى الذين يتلقون عالج ثنائي من م�سادات تكتل ال�سفيحات الدموية، رغم اأن هذا الأمر نادر احلدوث. بناء على 
ذلك اإذا كان املر�سى يتناولون الأ�سربين و التيكاجريلور من امل�ستح�سن اإيقاف العالج الثاين اإن اأمكن ذلك. بالإ�سافة اإىل ذلك ، ال�ستخدام املتتايل 
لليزر التخثري ال�سوئي وليزر التفتيت ال�سوئي قد يقلل من خطر حدوث نزيف حاد.
اإن�سداد الزاوية؛ ارتفاع �سغط العني؛ تقرير حالة؛  Nd-YAG؛ حتدمية؛ مثبطات تكتل ال�سفيحات الدموية؛ زرق  الكلمات املفتاحية: ب�سع القزحية؛ ليزر 
كولومبيا.
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anticoagulant agents, the number of such patients req- 
uiring a laser iridotomy while concomitantly being on 
antiplatelet therapy is increasing.
Case Report
A 63-year-old male patient with ischaemic heart disease, 
in whom a prophylactic laser iridotomy had been indic- 
ated, presented to Centro Oftalmológico Virgilio Galvis, 
Floridablanca, Colombia in 2016. At that time, he was 
taking two antiplatelet agents, ticagrelor and aspirin. 
Initially, a neodymium-doped yttrium aluminium garnet 
Significant hyphaema as a complication of laser iridotomy has rarely been reported.1–4 Massive hyphaema may cause secondary acute 
elevation of intraocular pressure (IOP) and corneal 
blood staining which may lead to serious visual morb- 
idity. Laser iridotomy is a common procedure since curr- 
ently it is performed prophylactically on most patients 
with narrow anterior chamber angles; the prevalence 
of this condition in adults varies according to race, 
from 0.7% in Brazil to 10% in China.5–7 Given the wide 
use of antiplatelet drugs in preventing thrombotic 
diseases and the increased frequency of patients taking 
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(Nd:YAG) laser iridotomy (VISULAS® YAG III, Carl 
Zeiss Meditec AG, Jena, Germany) was performed in 
the right eye (four laser shots each containing 6 mJ of 
power). A small amount of bleeding was noted but was 
stopped under digital pressure on the Abraham lens 
[Figure 1A]. When performing the second shot in the 
left eye, however, the iridotomy site started to bleed and 
the blood flow did not stop despite applying digital 
pressure. Over the subsequent ten minutes a hyphaema 
formed, filling approximately 75% of the anterior chamber 
and the IOP increased to 62 mmHg [Figure 1B].
Given the patient’s medical history of ischaemic 
heart disease, he was sent to the emergency department. 
Internal medicine advised to give an intravenous injection 
of mannitol (2 g/kg) over one hour and to discontinue 
the antiplatelet therapy. Topical treatment was started 
with prednisolone acetate (1%) four times a day and 
dorzolamide/timolol twice a day. By the next day, IOP 
had decreased to 14 mmHg. By the fourth day post-
procedure, the blood clot filled approximately 25% of 
the anterior chamber. Following the evaluation by the 
cardiologist, the patient resumed antiplatelet therapy.
Ten days after the iridotomy attempt, the anterior 
chamber of the left eye was free of blood and IOP was 
18 mmHg. The iridotomy site in that eye was not patent 
[Figure 1C]. Two months later, after the patient’s cardiol- 
ogist had temporarily suspended antiplatelet therapy, a 
new iridotomy was performed in the patient’s left eye 
without complications. This session used a sequential 
application of a yellow 577 nm laser (Pascal Streamline 
577, Topcon Medical Systems Inc., Oakland, New Jersey, 
USA) in order to photocoagulate the tissue and an 
Nd:YAG laser was used to create the perforation (VIS- 
ULAS® YAG III) [Figure 2]. At the last check-up visit 
two years later, the iridotomy was open and IOP was 
15 mmHg [Figure 3].
Discussion
Preventative laser iridotomies are currently performed 
in most patients with narrow anterior chamber angles; 
the prevalence of this condition in adults varies from 
0.7–10% depending on race.7–10 In addition, given the 
growing frequency of patients taking antiplatelet or 
anticoagulant agents, the number of patients requiring 
a laser iridotomy is increasing. Both photocoagulating 
(Argon laser: 514 nm or Nd:YAG frequency-doubled 
laser: 532 nm) and photodisrupting lasers (Nd:YAG: 
1064 nm) have been used to perform laser iridotomies; 
the use of the latter has become more common in the 
past three decades. Bleeding at the iridotomy site that 
stops under digital pressure on the Abraham lens has 
 
Figure 1: A: Photograph of the right eye of a 63-year-old male patient during a laser iridotomy showing mild bleeding from 
the iridotomy site. B: Photograph of the left eye showing massive hyphaema occupying approximately 75% of the anterior 
chamber. C: Photograph of the left eye ten days after the iridotomy attempt showing resolved hyphaema and non-patent 
iridotomy site (arrow).
 
Figure 2: A: Photograph of the iris stroma of the left eye of 
a 63-year-old male patient after focal photocoagulation 
with a yellow 577 nm laser during the second iridotomy 
procedure two months after hyphaema was resolved. 
Some tissue contraction (red circle) was observed. B: 
Completed iridotomy using a laser neodymium-doped 
yttrium aluminum garnet 1064 nm laser (red circle). No 
bleeding was evident.
 
Figure 3: Photograph of the left eye of a 63-year-old male 
patient two years after a successful iridotomy procedure 
that was still patent and had an intraocular pressure of 
15 mmHg.
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been reported in a wide range of cases, from 3% to 
approximately 50%.2,8–14 However, massive hyphaema 
has been rarely reported as a complication of Nd:YAG 
laser iridotomies in patients with uveitis or rubeosis 
and in some patients without apparent risk factors.1,2,4 
Bleeding seems to be less frequent with photocoagul- 
ating lasers because of the thermal coagulation effect. 
However, at least one case of significant hyphaema 
following peripheral iridotomy using an Argon laser 
has been reported.3 The sequential use of two different 
types of laser—photocoagulating and photodisruptive— 
has also been reported to diminish the risk of bleeding.13,14 
Antithrombotic medications are widely used to 
prevent both arterial or venous thromboembolisms, 
which can cause cerebrovascular or cardiovascular 
disease (e.g. myocardial infarction, ischaemic stroke 
and peripheral arterial disease leading to limb gangrene) 
usually related to arterial thrombosis or deep vein throm- 
bosis that can result in pulmonary embolism.15 Aspirin is 
the most commonly used antiplatelet medication which 
inhibits platelet cyclo-oxygenase-1 therefore blocking 
the synthesis of thromboxane A2. Another family of 
antiplatelet medications are the adenosine diphosphate 
(P2Y12) receptor inhibitors, including thienopyridines 
(e.g. clopidogrel and prasugrel) and the newer class of 
cyclopentyl triazolopyrimidines (e.g. ticagrelor).15–18 
Newer antiplatelet agents, like ticagrelor, are freq- 
uently used in addition to aspirin in order to reduce the 
rate of major adverse cardiovascular events in patients 
with ischaemic heart disease. This approach has been 
advantageous in terms of preventing thrombotic and 
major adverse cardiovascular events in high-risk patients. 
However, these combined therapies are associated with 
increased risk of bleeding.16,19–21 In the Platelet Inhibition 
and Patient Outcomes trial, ticagrelor was compared 
with clopidogrel, both in addition to aspirin, revealing a 
similar association with total major bleeding. Neverthe- 
less, ticagrelor exhibited higher and more consistent levels 
of inhibition of platelet aggregation across the dosing 
interval than clopidogrel and also a higher risk of both 
minor and major non-cardiac surgery related bleeding 
rates as well as during non-coronary artery-bypass-
grafting.15,17,18,21
Based on the results of a prospective controlled trial, 
Golan et al. suggested that there was no indication for 
discontinuing antiplatelet or anticoagulant treatment 
before an Nd:YAG laser iridotomy.12 However, Golan 
et al.’s study only included patients taking either aspirin, 
warfarin sodium or clopidogrel, with no patients on a 
dual antiplatelet therapy. None of the patients experienced 
massive hyphaema, yet the incidence of minor bleeding 
from the iridotomy site was comparable with and without 
the antiplatelet therapy (34.6% in both groups).12 How- 
ever, there were five cases (4.8%) of grade two bleeding 
—defined by the authors as not controlled by light 
pressure on the lens but no macroscopic hyphaema—
in the group of patients treated while taking antiplatelet 
agents, and only one case (1%) in the group of patients 
treated two weeks after discontinuing the medication. 
Although Golan et al. found this difference to be not 
statistically significant (P = 0.14); however, calculations 
made by the current authors based on the data publ- 
ished by Golan et al. and using a one-tailed Z score to 
compare the two population proportions, revealed the 
results to be significant (P = 0.046). 
In 2012, the evidence-based clinical practice guide- 
lines of the American College of Chest Physicians adv- 
ised that interrupting aspirin before non-cardiac surgeries 
may be reasonable for patients at low risk of cardio- 
vascular events due to the low benefit-to-risk ratio of 
continuing it perioperatively.22 On the other hand, in 
patients at moderate-to-high risk of perioperative adverse 
cardiovascular events, it may be preferable to continue 
the aspirin perioperatively. 
With regard to dual antiplatelet therapy in patients 
who require a coronary artery bypass graft, the guide- 
lines indicated that perioperative continuation of dual 
antiplatelet therapy has been related to an increased risk 
of bleeding. However, it was not clear whether there 
was a similarly increased risk for serious bleeding with 
perioperative continuation of dual antiplatelet therapy 
in patients having non-cardiac surgery and procedures.22 
Kong and Khan stated that although dual antiplatelet 
therapy increases the likelihood of bleeding in ophth- 
almic procedures, this complication is generally less 
significant than major adverse cardiac events in patients 
with coronary stents. Therefore, they advised that anti- 
platelet therapy should be continued in patients with 
coronary stents undergoing eye surgery.23 
Based on the joint consensus of several European 
and Asiatic scientific societies, Thachil advised stopping 
the second agent in dual antiplatelet therapy if the bleeding 
risk of a non-cardiac procedure was low.24 Similarly in a 
recent multidisciplinary consensus from Spain, Vivas et 
al. concluded that in patients receiving dual antiplatelet 
therapy and scheduled for an elective procedure, the 
first step should be to consider postponing the procedure 
if the patient has a moderate-to-high risk of thrombosis 
until the risk is lower. Once the risk is low, they recommend 
maintaining aspirin, unless contraindicated (e.g. in neuro- 
surgery) and withdrawing the second antiplatelet agent. 
If the thrombotic risk remains high, the decision to 
stop dual antiplatelet therapy will depend on the bleeding 
risk associated with the procedure. If the bleeding risk 
is low, they do not suggest stopping dual antiplatelet 
therapy but cases of moderate-to-severe risk of bleeding 
are more controversial and they advocate evaluating 
patients on a case-by-case basis within a multi-disciplinary 
team.25 
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Although the current patient was hypertensive 
and diabetic, he did not have renal failure. There were 
no signs of diabetic retinopathy and the iris did not 
show rubeosis. It is therefore difficult to state that a 
comorbidity could have played a role in the hyphaema 
development. On the other hand, suspicion that the 
origin of the haemorrhage had not been the iris was 
rejected since when performing a laser iridotomy, the 
risk of causing a lesion to other vascularised intraocular 
structures such as the ciliary body, has never been 
reported and is almost non-existent since a space 
separates the iris from more posterior structures and 
the laser energy acts focally. However, in view of the 
current case, it is important to note that there was 
no significant bleeding in the first eye treated in the 
patient and it is therefore not possible to establish a 
direct link between the dual antiplatelet therapy and 
massive bleeding during the peripheral iridotomy.
Conclusion
Massive hyphaema is a very rare complication foll- 
owing Nd:YAG laser iridotomy, which may occur in 
patients on dual antiplatelet therapy, as shown in the 
current case. The bleeding risk with a laser iridotomy 
is low; however, to avoid this potentially vision-threat- 
ening complication in patients on dual antiplatelet 
therapy, it is suggested to consult with an internist/
cardiologist in order to evaluate the option of tempor- 
arily discontinuing the two or at least the second antico- 
agulant, while continuing aspirin, for patients with low 
thrombotic risk. In patients with a high risk of throm- 
bosis, a case-by-case analysis should be undertaken with 
a cardiologist where the risk of bleeding during the proc- 
edure is weighed against the risk of developing a cardio- 
vascular thrombotic event. In addition, as sequential 
use of photocoagulating and photodisrupting lasers has 
been shown to have a lower risk of iris bleeding, this 
approach would be preferable in these patients. However, 
these recommendations are based on the limited evidence 
of this case report.
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